Evercore ISI initiated coverage of iRhythm (IRTC) with an In Line rating and $185 price target As a leader in the long term continuous monitoring market with unique AI differentiation, iRhythm’s multi parameter sensing should sustain the topline momentum, the analyst tells investors. However, shares are currently trading at slight premium to the peer set, which, while “justified,” causes the firm to start the stock with an In Line rating.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- Irhythm Technologies: Strategic Market Expansion and Clinical Efficacy Drive Buy Rating
- iRhythm Technologies: Strategic Partnerships and Growth Potential Drive Buy Rating
- Positive Buy Rating for Irhythm Technologies Supported by AMALFI Trial Success
- iRhythm announces results from AMALFI clinical trial
- iRhythm price target raised to $193 from $180 at Needham